PriceTargets.com logo

DocMorris - ZRSEF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$95.77 As of 04/24/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for ZRSEF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DocMorris Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZRSEF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZRSEF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for DocMorris in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $95.77.

This chart shows the closing price for ZRSEF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in DocMorris. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/9/2023HSBCUpgradeHold ➝ Buy
2/6/2023Jefferies Financial GroupUpgradeHold ➝ Buy
2/6/2023Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold
2/6/2023CitigroupUpgradeSell ➝ Neutral
11/15/2022Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellCHF 28 ➝ CHF 24
11/10/2022CitigroupDowngradeNeutral ➝ Sell
10/24/2022BarclaysBoost TargetCHF 35 ➝ CHF 48
10/24/2022Berenberg BankLower TargetCHF 70 ➝ CHF 30
10/19/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
10/18/2022Morgan StanleyInitiated CoverageEqual Weight
10/5/2022Deutsche Bank AktiengesellschaftLower TargetHold ➝ HoldCHF 76 ➝ CHF 47
9/27/2022BarclaysLower TargetEqual Weight ➝ Equal WeightCHF 61 ➝ CHF 48
8/22/2022Credit Suisse GroupLower TargetCHF 73 ➝ CHF 49
8/22/2022Deutsche Bank AktiengesellschaftLower TargetCHF 84 ➝ CHF 76
8/19/2022BarclaysLower TargetEqual Weight ➝ Equal WeightCHF 68 ➝ CHF 61
8/9/2022BarclaysDowngradeOverweight ➝ Equal Weight
7/12/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
6/22/2022Credit Suisse GroupInitiated CoverageUnderperform
6/7/2022BarclaysLower TargetOverweight ➝ OverweightCHF 178 ➝ CHF 173
6/6/2022Deutsche Bank AktiengesellschaftLower TargetCHF 420 ➝ CHF 180
5/12/2022Baader BankUpgradeBuyCHF 140
5/10/2022BarclaysInitiated CoverageOverweight
4/13/2022Berenberg BankLower TargetHold ➝ HoldCHF 230 ➝ CHF 135
3/29/2022UBS GroupLower TargetCHF 169 ➝ CHF 95
3/28/2022HSBCUpgradeReduce ➝ Hold
3/25/2022CitigroupDowngradeBuy ➝ Neutral
1/11/2022HSBCInitiated CoverageReduce
1/10/2022Jefferies Financial GroupLower TargetBuy ➝ BuyCHF 571 ➝ CHF 515
1/7/2022Stifel EuropeInitiated CoverageHold
1/7/2022Stifel NicolausInitiated CoverageHold
10/25/2021UBS GroupLower TargetSellCHF 257 ➝ CHF 250
10/8/2021Berenberg BankDowngradeBuy ➝ Hold
8/16/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
4/27/2021UBS GroupReiterated RatingSell
4/23/2021Berenberg BankReiterated RatingBuy
3/30/2021UBS GroupReiterated RatingSell
3/23/2021Morgan StanleyInitiated CoverageOverweight
2/8/2021Berenberg BankReiterated RatingBuy
1/29/2021CitigroupDowngradeBuy ➝ Neutral
1/22/2021BarclaysReiterated RatingOverweight
7/17/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
7/7/2020BarclaysReiterated RatingOverweight
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
DocMorris logo
DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers prescription and over-the-counter medicines, consumer health products, beauty and personal care products, nutritional supplements, painkillers, and first aid products. It also provides professional health care services. The company sells its products to online mail-order pharmacies, and private individuals under the PromoFarma by DocMorris, TeleClinic, and DocMorris brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
Read More

Today's Range

Now: $95.77
Low: $95.77
High: $95.77

50 Day Range

MA: $96.54
Low: $88.60
High: $108.05

52 Week Range

Now: $95.77
Low: $33.00
High: $108.05

Volume

N/A

Average Volume

117 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of DocMorris?

The following Wall Street sell-side analysts have issued stock ratings on DocMorris in the last year: HSBC Holdings plc.
View the latest analyst ratings for ZRSEF.

What is the current price target for DocMorris?

0 Wall Street analysts have set twelve-month price targets for DocMorris in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for DocMorris in the next year.
View the latest price targets for ZRSEF.

What is the current consensus analyst rating for DocMorris?

DocMorris currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZRSEF will outperform the market and that investors should add to their positions of DocMorris.
View the latest ratings for ZRSEF.

What other companies compete with DocMorris?

Other companies that are similar to DocMorris include Alibaba Health Information Technology, Allstar Health Brands, Clicks Group, Fire & Flower and High Tide. Learn More about companies similar to DocMorris.

How do I contact DocMorris' investor relations team?

DocMorris' physical mailing address is Walzmühlestrasse 60, Frauenfeld, Thurgau (Thurgovia). The company's listed phone number is (152) 724-0020. The official website for DocMorris is www.zurrosegroup.com. Learn More about contacing DocMorris investor relations.